Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Ruling Sets A Precedent That Could Give FDA Pause

This article was originally published in The Pink Sheet Daily

Executive Summary

March 23 ruling ordered FDA to reconsider a citizen petition requesting Plan B access for women of all ages.

You may also be interested in...



Plan B Rulemaking Intended To Establish Enforcement Procedures – Crawford

The question of how to enforce an age-limit for OTC availability of Barr Labs' Plan B - rather than whether dual status for the drug could exist at all - was the main driver behind FDA's initiation of a rulemaking on the Rx-to-OTC switch application for the emergency contraceptive, according to former FDA Commissioner Lester Crawford

US Consumer Health Industry In 2023: Mandatory Listing Has Supplement Sector’s Attention

Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight reports here on whether support will emerge in Congress for FDA to gain MPL authority for all supplements sold in US.

US FDA ‘Punt’ On Hemp Rulemaking Frustrates, Confuses Supplement Industry

Industry trade groups say FDA decision against starting rulemaking for lawful use of hemp ingredients is not only overdue but failed to clear the air for businesses making or using the ingredients.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel